Humacyte, Inc.
HUMA
$0.58
-$0.02-2.67%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 34.88% | -4.26% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.88% | -4.26% | -- | -- | -- |
| Cost of Revenue | -10.38% | 29.29% | 14.67% | -23.52% | -8.98% |
| Gross Profit | 11.02% | -30.40% | -12.41% | 26.81% | 10.25% |
| SG&A Expenses | 4.13% | -4.93% | 2.48% | 4.15% | 34.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.57% | 17.74% | 11.45% | -16.84% | -0.58% |
| Operating Income | 7.00% | -18.22% | -9.78% | 19.33% | 1.60% |
| Income Before Tax | 2.27% | -145.02% | -18.45% | 55.33% | 33.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 2.27% | -145.02% | -18.45% | 55.33% | 33.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.27% | -145.02% | -18.45% | 55.33% | 33.54% |
| EBIT | 7.00% | -18.22% | -9.78% | 19.33% | 1.60% |
| EBITDA | 7.20% | -19.92% | -10.53% | 20.75% | 1.99% |
| EPS Basic | 35.12% | -130.02% | 19.47% | 66.31% | 49.04% |
| Normalized Basic EPS | 28.12% | -27.61% | 67.10% | 45.02% | 22.38% |
| EPS Diluted | 33.97% | -130.64% | 19.47% | 66.31% | 49.52% |
| Normalized Diluted EPS | 28.12% | -27.85% | 67.10% | 45.02% | 22.38% |
| Average Basic Shares Outstanding | 50.66% | 50.31% | 47.09% | 32.58% | 30.43% |
| Average Diluted Shares Outstanding | 50.66% | 50.01% | 47.09% | 32.58% | 30.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |